[Liver transplantation for the treatment of hepatocellular carcinoma].
OBJECTIVE
To retrospectively evaluate the clinical outcomes of liver transplantation for patients with hepatocellular carcinoma (HCC).


METHODS
The clinical data of 88 consecutive HCC patients who underwent orthotopic liver transplantation between 2002. 4 and 2004. 7 were retrospectively reviewed. HCC stage of those patients were defined according to the pTNM classification system of UICC. All patients were followed up for more than 12 months after liver transplantation. The recurrence and overall survival rate were evaluated by univariate and multivariate analysis with SAS software.


RESULTS
The cumulative 1-year recurrence rate of stage I, II, III and IV after liver transplantation was 0%, 4.8%, 40.0% and 71.3%, respectively (P < 0.01). The cumulative 1-year overall survival rate of stage I, II, III and IV was 100%, 95.2%, 71.5% and 41.7%, respectively (P < 0.01).


CONCLUSIONS
Liver transplantation may be suitable for stage I or II hepatocellular cancer patients and improve their prognosis, while it is not suitable for stage IV HCC patients.
Chen
Xin-guo
XG
Department of Liver Transplantation, General Hospital of Armed Police Forces, Beijing 100039, China.
Zhu
Xiao-dan
XD
Li
Wei
W
Liu
Yu
Y
Zou
Wei-long
WL
Niu
Yu-jian
YJ
Wu
Feng-dong
FD
Guan
Zhao-jie
ZJ
Yue
Yang
Y
D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome